Jump to ContentJump to Main Navigation

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board Member: Fujimoto, Jiro / Groner, Bernd / Hubalek, Michael / Morfin, Robert / Saad, Farid / Schally, Andrew V. / Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Campagnoli, Carlo / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Danza, Giovanna / Darbre, Philippa D. / Daxenbichler, Günter / Kloet, Ronald / Nicola, Alejandro F. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Flores-Morales, Amilcar / Garcia-Segura, Luis M. / Gee, J.M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Hilakivi-Clarke, Leena / Hampl, Richard / Iwase, Hirotaka / Jordan, V.Craig / Klocker, Helmut / Kurebayashi, Junichi / Labrie, Fernand / Luu-The, Van / Mendelson, Carole R. / Mück, Alfred O. / Nicholson, Robert / Norman, Anthony W. / O'Malley, Bert W. / Rafestin-Oblin, Marie-Edith / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Sanchez, Edwin R. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Verhoeven, Guido / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Ylikomi, Timo / Yu, Qi

12 Issues per year



The antihormonal preventive therapy of breast cancer and prostate cancer

1 / Rudolf Morant1 / Florian Otto1

1Tumour and Breast Centre ZeTuP, St. Gallen, Switzerland

Corresponding author: Professor Dr. med. Hans-Jörg Senn, Scientific Director, Tumor and Breast Centre ZeTuP (Early Detection, Treatment and Prevention), Rorschacher Strasse 150, CH-9006 St. Gallen, Switzerland Phone: +41-71-243-0043, Fax: +41-71-243-0044, Website 1: www.zetup.ch, Website 2: www.oncoconferences.ch

Citation Information: Hormone Molecular Biology and Clinical Investigation. Volume 5, Issue 2, Pages 117–123, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: 10.1515/HMBCI.2010.079, March 2011

Publication History

Published Online:


With the continuing increase of median life expectancy of important segments of the world's population, cancer incidence, as well as cancer related morbidity and mortality, are constantly increasing, especially for developing countries and for breast and prostate cancer, the predominant gender-associated cancer types. In addition to continuing, with more and more expensive efforts to develop new and more effective cancer treatments, it is health-politically and medico-professionally important to realise that only successful approaches to primary cancer prevention of major and frequent cancer types will be able to change this socially and economically unfavourably outlook. It is therefore encouraging to see that primary (or pharmacologic, interventional) cancer prevention programs have been successfully developed over the past decade for individuals at elevated risk for breast and prostate cancer on the basis of several scientifically well-conducted, prospective chemoprevention trials, mainly with synthetic anti-hormones (anti-estrogens and anti-androgens) in the USA, in Europe and Australia. This paper summarises the presently published results and design of several completed and some currently running primary cancer prevention trials in breast cancer and prostate cancer, and also points to the important obstacles for their conduct and translation into general practice in the broader populations at risk outside of clinical prevention research.

Keywords: breast cancer chemoprevention; chemoprevention; pharmacologic cancer prevention; primary cancer prevention; prostate cancer chemoprevention

Comments (0)

Please log in or register to comment.